Pharvaris (NASDAQ:PHVS) Insider Wim Souverijns Sells 10,000 Shares

Pharvaris N.V. (NASDAQ:PHVS) insider Wim Souverijns sold 10,000 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $29.92, for a total transaction of $299,200.00. Following the sale, the insider directly owned 45,111 shares of the company’s stock, valued at $1,349,721.12. This represents a 18.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Pharvaris Stock Performance

NASDAQ:PHVS opened at $28.95 on Wednesday. The company has a market capitalization of $1.89 billion, a PE ratio of -9.10 and a beta of -2.34. The company has a 50 day simple moving average of $28.26 and a two-hundred day simple moving average of $26.68. Pharvaris N.V. has a fifty-two week low of $15.46 and a fifty-two week high of $33.33.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. Research analysts predict that Pharvaris N.V. will post -3.25 EPS for the current year.

Institutional Trading of Pharvaris

Large investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Pharvaris during the 4th quarter worth approximately $35,000. JPMorgan Chase & Co. grew its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in Pharvaris in the 3rd quarter valued at $75,000. Barclays PLC acquired a new stake in Pharvaris in the 4th quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Pharvaris in the 4th quarter valued at $86,000.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates for Pharvaris across multiple quarters and fiscal years, including higher forecasts for FY2026 through FY2030, and maintained a Buy rating with a $60 price target.
• Neutral Sentiment: Pharvaris recently reported a smaller-than-expected quarterly loss, with EPS of ($0.70) versus the consensus estimate of ($0.82), which may support sentiment but does not change the company’s near-term loss profile.
• Negative Sentiment: Insider selling by Director Robert Glassman and insider Wim Souverijns, both of whom sold 10,000 shares, may temper enthusiasm slightly because it can be viewed as reduced insider confidence. SEC filing for Robert Glassman sale SEC filing for Wim Souverijns sale

Analysts Set New Price Targets

A number of research firms have weighed in on PHVS. Wall Street Zen raised shares of Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, March 3rd. Citizens Jmp reduced their price objective on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 13th. Wedbush raised their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $49.18.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.